Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Pain Management Devices Market to Hit USD 5,835.8 Million by 2029 with 9.1% CAGR…
Browse in-depth TOC on "Pain Management Devices Market" Browse in-depth TOC on "Pain Management Devices Market" 294 - Tables 64 - Figures 297 - Pages High procedural cost, and increasing product recalls are likely to hamper the growth of pain management devices market Based on type, the neurostimulation devices segment held the largest share of of the pain management devices market. Due to the large number of ongoing clinical studies to establish the efficacy and safety...
PR Newswire
18/10/2024
Cattle & Porcine/Swine Reproductive Diseases Market to Hit USD 975.8 Million by…
Browse in-depth TOC on "Cattle & Porcine/Swine Reproductive Diseases Market" Browse in-depth TOC on "Cattle & Porcine/Swine Reproductive Diseases Market" 335 - Tables 66 - Figures 333 - Pages In this report, the cattle & porcine/swine reproductive diseases market is segmented into product type, diseases type, animal type, end user type and region. Based on product type,the cattle & porcine/swine reproductive diseases market is divided into devices,...
PR Newswire
18/10/2024
Amorepacific Presents Latest Research at IFSCC
SEOUL, South Korea, Oct. 18, 2024 /PRNewswire/ -- Amorepacific presented its latest research at this year's International Federation of Societies of Cosmetic Chemists conference (34th Congress IFSCC BRAZIL) held in Foz do Iguaçu, Brazil, from October 14 to 17. SEOUL, South Korea , Oct. 18, 2024 /PRNewswire/ -- Amorepacific presented its latest research at this year's International Federation of Societies of Cosmetic Chemists conference (34th Congress IFSCCBRAZIL ) held in Foz do...
PR Newswire
18/10/2024
Endo Presents Data at the American Society of Podiatric Surgeons (ASPS) Annual…
"We're pleased to share data with healthcare providers about our plantar fibromatosis clinical trials to help improve patient care and discuss our clinical development program," said James P. Tursi, M.D., Executive Vice President, Global Research & Development at Endo. "These presentations also demonstrate our growth strategy to develop a musculoskeletal pipeline serving those suffering from this and other burdensome conditions." "We're pleased to share data with…
PR Newswire
18/10/2024
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive OfficerCambridge UK,18 October2024– ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as Chief Executive Officer of ViaNautis. He will succeed Co-Founder and CEO Dr Francesca Crawford who has been stepping down from her role.Dr Adi Hoess brings a wealth of experience to ViaNautis, having previously...
Nasdaq GlobeNewswire
18/10/2024
KFSHRC Leads Healthcare Intelligence in Diagnostics and Patient Care
RIYADH, Saudi Arabia, Oct.18, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is contributing to global healthcare innovation, leveraging artificial intelligence (AI) and robotics to enhance diagnostics accuracy, streamline patient care, and improve treatment outcomes.Central to this is the Centre for Healthcare Intelligence (CHI), which utilizes 20 AI applications to advance medical imaging, patient flow, and resource management, fostering a...
Nasdaq GlobeNewswire
18/10/2024
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of…
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali ®(ribociclib) in combination with an aromatase inhibitor 1 Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients...
Nasdaq GlobeNewswire
18/10/2024
City microbes surviving on disinfectants, research reveals
A new study published in the journal Microbiome has identified novel strains of microbes that have adapted to use the limited resources available in cities and shown that our everyday behaviour is changing the makeup of microorganisms in indoor environments. A new study published in the journalMicrobiome has identified novel strains of microbes that have adapted to use the limited resources available in cities and shown that our everyday behaviour is changing the makeup of microorganisms...
PR Newswire
18/10/2024
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily…
Bagsværd, Denmark, 18 October 2024– Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo ®(concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors. Haemophilia is a rare bleeding disorder that impairs the body's ability to make blood clots, a process needed...
Nasdaq GlobeNewswire
18/10/2024
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing…
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a.177 Lu)Companies enter into an additional manufacturing and supply agreement for NTP to produce and supply n.c.a.177 Lu to ITMExtending the collaboration strengthens production capacity and enhances the global supply of valuable medical radioisotopesGarching / Munich, Germany, and Pretoria, South Africa, October 18, 2024 –ITM Isotope Technologies...
Nasdaq GlobeNewswire
18/10/2024
Taiwan's Machinery Enterprises Are Powering Industrial Automation
To explore collaborations with leading companies in automation and machinery, TAITRA can connect you with top Taiwanese suppliers in the field:https://innovation.taitra.org.tw/en/supplier-list To explore collaborations with leading companies in automation and machinery, TAITRA can connect you with top Taiwanese suppliers in the field: https://innovation.taitra.org.tw/en/supplier-list Or email:
[email protected]
Solving challenges for implementing...
PR Newswire
18/10/2024
Chiesi launches innovation platform focused on partnership and patient care: The…
The Impulse is stepping in to fill the growing demand for innovative solutions that meet the real needs of patients. By creating a collaborative space for researchers, start-ups, and innovators to work together, The Impulse is driving forward-thinking healthcare solutions—from digital health advancements to sustainable patient care models—that have the potential to transform how we think about and deliver healthcare. The Impulse is stepping in to fill the growing demand for innovative…
PR Newswire
18/10/2024
Medeze Group Awarded Frost & Sullivan's 2024 Southeast Asia Company of the Year…
Medeze has been a dominant player in Southeast Asia's stem cell banking industry since its establishment in 2010. It has distinguished itself with a diverse portfolio that meets various medical demands, including autologous and allogeneic stem cell treatments for aesthetic concerns and therapeutic applications. In addition to its innovative therapies, Medeze's strategic expansion initiatives have solidified its leadership in the Southeast Asian industry. The company has expanded its presence to…
PR Newswire
18/10/2024
Keio University Research: Genomic Insights for Personalized Cancer Treatment
https://research-highlights.keio.ac.jp/2024/10/c.html https://research-highlights.keio.ac.jp/2024/10/c.html Caption: [Fig. 1A, Fig. 4A, Fig. 5BC, from the paper [1] https://doi.org/10.1158/2159-8290.CD-23-0902 Background The advent of next-generation sequencing (NGS) has transformed our understanding of cancer, enabling detailed analyses of genetic mutations driving cancer development. Large-scale genomic studies like The Cancer Genome Atlas (TCGA) and the AACR Project...
PR Newswire
18/10/2024
From China to the World: Botanee brings innovation to global cosmeceutical R&D…
"This is an outstanding international recognition of Botanee's years of research and innovation in the field. We are currently investing to create more opportunities that bring more of our award-winning plant-based technologies to consumer around the world," said Zhong Wei, PR Director of Botanee Group. "This is an outstanding international recognition of Botanee's years of research and innovation in the field. We are currently investing to create more opportunities that bring…
PR Newswire
18/10/2024
200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug…
Key Takeaways from the Antibody-drug Conjugates in Oncology Pipeline Report Request a sample and discover the recent advances in the antibody-drug conjugates in oncology market @Antibody-drug Conjugates in Oncology Competitive Landscape Report Antibody-drug Conjugates in Oncology Overview Antibody-drug conjugates (ADCs) represent a cutting-edge approach in oncology, combining the targeting ability of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs...
PR Newswire
17/10/2024
Alkermes to Report Third Quarter Financial Results on October 24, 2024
About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a…
PR Newswire
17/10/2024
AB Science provides an update on the application for conditional marketing…
PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISParis, 17 October, 2024, 7.30pm CETAB Science SA(Euronext - FR0010557264 - AB) today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following a vote adopted during the...
Nasdaq GlobeNewswire
17/10/2024
Casino Group: Statutory buyout proceedings - Cnova
Casino has initiated statutory buyout proceedings in accordance with Article 2:92a of the Dutch Civil Codeto acquire all issued shares in Cnova Paris, 17 October 2024Casino Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR0000125585) hereby informs as follows: on 17 October 2024, Casino Guichard-Perrachon S.A. (" Casino ") has initiated statutory buyout proceedings ( uitkoopprocedure ) in accordance with Article 2:92a of the Dutch Civil Code (the " DCC ") at the…
Nasdaq GlobeNewswire
17/10/2024
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for…
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking 1cytokine technology in oral presentations selected for international conferences: TheFestival of Biologicsin Basel, Switzerland (October 17, 2024)The 16 thAnnualProtein & Antibody Engineering Summit (PEGS) Europe Summitin Barcelona, Spain (November 7, 2024)TheAntibody Therapeutics Xchange...
Nasdaq GlobeNewswire
17/10/2024
EssilorLuxottica: Q3/9M 2024 Revenue - Revenue keeping a solid 4% growth
Q3/9M 2024 RevenueRevenue keeping a solid 4% growth Group's revenue up 4.0% at constant exchange rates 1in Q3, +4.9% year to dateRevenue positive in both segments in all the regions in Q3North America up low-single digit, with sun retail turning positive at the end of the quarterEMEA up mid-single digit, driven by both Professional Solutions and Direct to ConsumerChina kept positive, despite macroeconomic headwinds, supported by Stellest 40% growthRay-Ban...
Nasdaq GlobeNewswire
17/10/2024
Allure Bridals Reveals Spring 2025 Collections
The namesake Allure Bridals collection continues its tradition of timeless elegance with romantic lacework that exudes classic beauty and warmth. The Allure Couture collection includes show-stopping styles with majestic detailing such as structured bodices and laced corsets. The addition of luxurious detachable sleeves and trains gives an opulent touch perfect for a regal look. Allure Romance's bridal looks feature floral motifs and refined textiles like Mikado and dove satin, while Chantilly…
PR Newswire
17/10/2024
Virbac: Strong revenue growth as of the end of September at +12.6% and +8.6% at…
KEY FIGURES Revenue at the end of September €1 042.1MGrowth at constant exchange ratesand scope 1 +8.6%including companion animals +11.9%farm animals +3.2%Growth at constantexchange rates 2 +14.0% Overallchange +12.6% 1 growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the...
Nasdaq GlobeNewswire
17/10/2024
Casino Group: Appointments
Casino Group continues the overhaul of its purchasing strategy and organisationPauline Glaziou appointed Group Merchandise Director Paris, 17 October 2024 Pauline GLAZIOUhas been appointed Group Merchandise Director and will chair Casino Group's central purchasing unit as of 1 November 2024. She joins Casino Group's Executive Committee, where women are the majority following of this appointment.Pauline was previously Commercial Director of Food and Beauty at Monoprix, after having...
Nasdaq GlobeNewswire
17/10/2024
Altri Comunicati